Teprotumumab shows robust phase 3 efficacy for thyroid eye disease
- Posted on: Mar 6 2019
- Leave a response
Horizon Pharma announced positive topline results in a confirmatory phase 3 trial evaluating teprotumumab for active thyroid eye disease (TED).
Source: AAO
Posted in: Uncategorized
